ChemoMetec A/S

As of June 30, 2026, ChemoMetec A/S carries a market capitalization of 6.27B, placing it among publicly traded companies globally. Its enterprise value stands at 5.98B, reflecting the total theoretical takeover cost after accounting for cash holdings and debt obligations.

ChemoMetec A/S's next confirmed earnings release is scheduled for February 3, 2027.

As of June 30, 2026, ChemoMetec A/S has 17.30M shares outstanding.

These figures are as of June 30, 2026.

As of June 30, 2026, ChemoMetec A/S maintains a current ratio of 4.09, meaning it holds 4.1x the short-term assets needed to cover near-term liabilities.

These figures cover the twelve months ended June 30, 2026.

As of the close on October 22, 2026, ChemoMetec A/S's stock has declined approximately 12.82% over the past 52 weeks. The 50-day moving average sits at 523.97, while the 200-day moving average is 444.12.

As of June 30, 2026, ChemoMetec A/S holds 293.56M in cash and equivalents against 4.59M in total debt, resulting in a net debt position of -288.64M. Total book value stands at 725.39M, with working capital of 396.56M providing operational flexibility.